massarray assay design v3.0.0 (Metabion International AG)
90
Structured Review
Metabion International AG
massarray assay design v3.0.0
Massarray Assay Design V3.0.0, supplied by Metabion International AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+assay+design+v3%2E0%2E0/massarray+assay+design+v3+0+0/pm24024896-72-11-21
Average 90 stars, based on 1 article reviews
Massarray Assay Design V3.0.0, supplied by Metabion International AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+assay+design+v3%2E0%2E0/massarray+assay+design+v3+0+0/pm24024896-72-11-21
Average 90 stars, based on 1 article reviews
massarray assay design v3.0.0 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Amplification:Article Title: ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Article Snippet: For over 50 years, 5-fluorouracil (5-FU) has been in use as the backbone of chemotherapy treatment regimens for a wide range of cancers with approximately two million patients treated worldwide each year [1].. However, drug resistance and severe toxicity, including mucositis, diarrhea, neutropenia, and nausea and vomiting, in up to 15–20% of treated patients, often leading to dose limitation or treatment discontinuation, are still major problems in the clinical use of this drug [2,3].. The development of individualized treatment strategies including the use of predictive genetic host factors to manage toxicity and improve outcome remains an option that has so far been of limited success, presumably because important determinants are still unknown [4]. |